Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11277012 | 0.84 | HTR2B (0.40) | HTR2AHTR2CHRH1MAOAMAOB | |
| SCHEMBL11272147 | 0.82 | MAOB (0.43) | HTR2AHTR2CHRH1MAOAMAOB | |
| SCHEMBL9530007 | 0.81 | NR3C2 (0.44) | MAOBDRD2DRD3 | |
| SCHEMBL9528836 | 0.81 | TERT (0.42) | HTR2AHTR2CHRH1MAOBTERT | |
| SCHEMBL10881346 | 0.81 | KMT2A (0.39) | HTR2AHTR2CHRH1KMT2ANPC1 | |
| SCHEMBL10559305 | 0.81 | DRD2 (0.42) | HTR2AHTR2CHRH1MAOBDRD2 | |
| SCHEMBL4465669 | 0.79 | MAOA (0.59) | HTR2AHTR2CHRH1MAOAMAOB | |
| SCHEMBL10238629 | 0.78 | HTR2A (0.47) | HTR2AHTR2CHRH1MAOAMAOB | |
| SCHEMBL20829248 | 0.78 | HTR2A (0.43) | HTR2AHTR2CHRH1MAOAMAOB | |
| SCHEMBL1367244 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHRH1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017044575-A1 | CONSTRAINED BENZHYDRYL SULFONAMIDES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | disclosed |
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH | 2004-02-12 | — | — | US | disclosed |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | KLINGE PHARMA GMBH | 2003-08-28 | — | — | US | disclosed |
| EP-0912176-B1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6451816-B1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | disclosed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0085870-B1 | DIBENZ(B,E)OXEPIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KYOWA HAKKO KOGYO CO., LTD (JP) | 1986-06-11 | — | — | EP | disclosed |
| US-4335122-A | DIURETICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | ALK, ANXA1, ANXA11 | HTR2A 3320/4885HTR2C 4101/4885HRH1 122/4885 |
| US-20040029861-A1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | ALK, IDO1, PDXK | HTR2A 1986/4885HTR2C 2910/4885HRH1 80/4885 |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | ALK, TYMP, ANXA1 | HTR2A 2822/4885HTR2C 4108/4885HRH1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.